XML 70 R43.htm IDEA: XBRL DOCUMENT v3.20.1
Summary of Significant Accounting Policies (Details Narrative) - USD ($)
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Jan. 02, 2019
Dec. 31, 2017
Inventory [1] $ 1,456,597 $ 1,456,597    
Severance expenses 79,190 120,753    
Warranty expenses 4,699 1,173    
Derivative liability       $ 768,249
Increase in additional paid-in capital 2,505,723      
Right-of-use assets 187,232    
Operating liabilities 147,042      
Accounting Standards Update 2016-02 [Member]        
Lease term     12 months  
Right-of-use assets     $ 225,000  
Operating liabilities     $ 225,000  
Accounts Receivable [Member] | One Customer [Member]        
Concentration risk, amount 99,888      
Inception Through December 2004 [Member]        
Cumulative research and development $ 93,300      
[1] Management evaluates whether inventory reserve for slow-moving or obsolete items is required. To date, as a result of low volume of revenues generated from the sales of the GlucoTrack® model DF-F glucose monitoring device the Group has recorded reserves with respect to its inventory in the amount of approximately US$ 1,457 thousand. (of which an amount of US$ 700 thousand was recognized in the fourth quarter of 2018).